An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 6, 2007, Pages 653-661

  Haddad, Nadine ^a,b   Eugster, Erica ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Aromatase inhibitors; McCune Albright syndrome; Testotoxicosis

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; CYPROTERONE ACETATE; DESLORELIN; ESTROGEN; FADROZOLE; FLUTAMIDE; GESTAGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; KETOCONAZOLE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SPIRONOLACTONE; TAMOXIFEN; TESTOLACTONE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ALBRIGHT SYNDROME; BILIRUBIN BLOOD LEVEL; CHILD GROWTH; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GROWTH RATE; HAND FOOT SYNDROME; HORMONE INHIBITION; HUMAN; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MUSCLE WEAKNESS; OVARY DISEASE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRECOCIOUS PUBERTY; PRURITUS; REVIEW; RISK FACTOR; SIDE EFFECT; TESTOTOXICOSIS;

EID: 34447326148     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.6.653     Document Type: Review

References (47)

1. Albright F, Butler A, Hampton A, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 1936; 216: 727-746.
2. McCune D. Osteitis fibrosa cystica: the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 1936; 52: 743-744.
3. de Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M, Cisternino M, de Sanctis V, Lucci M, Franzese A, Ghizzoni L, Pasquino AM, Segni M, Rigon F, Saggese G, Bertelloni S, Buzi F. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J Pediatr Endocrinol Metab 1999; 12: 817-826.
4. s. J Pediatr 1993; 123: 509-518.
5. Hannon TS, Noonan K, Steinmetz R, Eugster EA, Levine MA, Pescovitz OH. Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone? J Pediatr 2003; 142: 532-538.
6. Roman R, Johnson MC, Codner E, Boric MA, aVila A, Cassorla F. Activating GNAS1 gene mutations in patients with premature thelarche. J Pediatr 2004; 145: 218-222.
7. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-1695.
8. Collins MT, Shenker A. McCune Albright syndrome: new insights. Curr Opin Endocrinol Diabetes 1999; 6: 119-125.
9. Schmidt H, Kiess W. Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab 1998; 11: 77-81.
10. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab 1999; 12: 681-686.
11. Nabhan Z, West, K, Eugster E. Oophorectomy in McCune Albright syndrome: a case of mistaken identity. J Pediatr Surg; in press.
12. Wasniewska M, Matarazzo P, Weber G, Russo G, Zampolli M, Salzano G, Zirilli G, Bertelloni S; Italian Study Group for Alterations of Gs alpha Protein Function. Clinical presentation of McCune-Albright syndrome in males. J Pediatr Endocrinol Metab 2006; 19 (Suppl 2): 619-622.
13. Wasniewska M, De Luca F, Bertelloni S, Matarazzo P, Weber G, Crisafulli G, Valenzise M, Lala R. Testicular microlithiasis: an unreported feature of McCune-Albright syndrome in males. J Pediatr 2004; 145: 670-672.
14. Comite F, Shawker TH, Pescovitz OH, Loriaux DL, Cutter GB Jr. Cyclical ovarian function resistant to treatment with an analogue of luteinizing hormone releasing hormone in McCune-Albright syndrome. N Engl J Med 1984; 311: 1032-1036.
15. Pescovitz OH, Cassorla F, Comite F, Loriaux DL, Cutler GB Jr. LHRH analog treatment of central precocious puberty complicating congenital adrenal hyperplasia. Ann NY Acad Sci 1985; 458: 174-181.
16. Laven JS, Lumbroso S, Sultan C, Fauser BC. Dynamics of ovarian function in an adult woman with McCune-Albright syndrome. J Clin Endocrinol Metab 2001; 86: 2625-2630.
17. Matarazzo P, Lala R, Andreo M, Einaudi S, Altare F, Viora E, Buzi F, De Luca F, De Sanctis V, Rigon F, Wasniewska M, de Sanctis L, de Sanctis C; Study Group for Gs alpha Protein Related Diseases of the Italian Society for Pediatric Endocrinology and Diabetes. McCune-Albright syndrome: persistence of autonomous ovarian hyperfunction during adolescence and early adult age. J Pediatr Endocrinol Metab 2006; 19 (Suppl 2): 607-617.
18. Feuillan PP. McCune-Albright syndrome. Curr Ther Endocrinol Metab 1994; 5: 205-209.
19. Carani C, Pacchioni C, Baldini A, Zini D. Effects of cyproterone acetate, LHRH agonist and ovarian surgery in McCune-Albright syndrome with precocious puberty and galactorrhea. J Endocrinol Invest 1988; 11: 419-423.
20. Sorgo W, Kiraly E, Homoki J, Heinze E, Teller WM, Bierich JR, Moeller H, Ranke MB, Butenandt O, Knorr D. The effects of cyproterone acetate on statural growth in children with precocious puberty. Acta Endocrinol (Copenh) 1987; 115: 44-56.
21. Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol Metab 1999; 12: 81-83.
22. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol 2006; 254-255: 207-216.
23. Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77: 647-651.
24. Nunez SB, Calis K, Cutler GB Jr., Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003; 88: 5730-5733.
25. Feuillan PP, Calis K, Hill S, Robey P, Collins M. Letrozole treatment of precocious puberty in girls with the McCune Albright syndrome. Proceedings of the Pediatric Academic Societies Annual Meeting, Seattle, WA. Pediat Res 2003; 136A.
26. Feuillan P, Calis K, Hill S, Shawker T, Robey P, Collins M. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007; April 3, epub.
27. Mieszczak J, Lowe E, Plourde P, Eupter E. Anastrozole treatment of precocious puberty in girls with McCune-Albright syndrome. Abstract presented at the LWPES Meeting, Toronto, May 2007.
28. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93: 1449-1457.
29. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143: 60-66.
30. Honig S, Wysowski DK, Beitz J. Uterine sarcoma and tamoxifen: poor prognosis compared to endometrial adenocarcinoma. In: Proc ASCO, 2002; 41a.
31. Lewis-Wambi JS, Jordan VC. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis 2005; 24: 93-105.
32. Zacharin M. Paediatric management of endocrine complications in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2005; 18: 33-41.
33. Rousseau-Merck MF, Misrahi M, Atger M, Loosfelt H, Milgrom E, Berger R. Localization of the human luteinizing hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21. Cytogenet Cell Genet 1990; 54: 77-79.
34. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365: 652-654.
35. Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole. J Clin Endocrinol Metab 1987; 64: 328-333.
36. Reiter EO, Norjavaara E. Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev 2005; 3: 77-86.
37. Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab 1983; 57: 571-579.
38. Itoh K, Nakada T, Kubota Y, Suzuki H, Ishigooka M, Izumi T. Testotoxicosis proved by immunohistochemical analysis and successfully treated with cyproterone acetate. Urol Int 1996; 57: 199-202.
39. Holland FJ. Gonadotropin-independent precocious puberty. Endocrinol Metab Clin North Am 1991; 20: 191-210.
40. Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985; 312: 1023-1028.
41. Santen RJ, Van den Bossche H, Symoens J, Brugmans J, DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983; 57: 732-736.
42. Babovic-Vuksanovic D, Donaldson MD, Gibson NA, Wallace AM. Hazards of ketoconazole therapy in testotoxicosis. Acta Paediatr 1994; 83: 994-997.
43. Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320: 496-502.
44. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84: 175-178.
45. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006; 149: 416-420.
46. Fradet Y. Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev Anticancer Ther 2004; 4: 37-48.
47. Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47 (Suppl): 70-79; discussion 80-84.